Gefitinib CAS 184475-35-2 API Active Pharmaceutical Ingredient

Product Description:

Product Name: Gefitinib CAS NO: 184475-35-2

Synonyms:

Iressa;

N-(3-Chloro-4-fluorophenyl)-7-metho-xy-6-(3-morpholinopropoxy)quinazolin-4-amine;

Irressat;

Chemical & Physical Properties:

Appearance: Light-yellow crystalline powder

Assay :≥98.0%

Density: 1.322g/cm3

Boiling Point: 586.8℃ at 760 mmHg

Melting Point: 119-120℃

Flash Point: 308.7℃

Refractive Index: 1.621

Vapor Pressure: 0mmHg at 25℃

Safety Information:

Symbol: GHS07

Signal Word: Warning

Safety Statements: S24/25; S36; S26

HS Code: 29143900

WGK Germany: 3

RTECS: HP1149700

Risk Statements: R36/37/38

Hazard Code: Xi

Caution Statements: P301 + P312 + P330; P305 + P351 + P338

Hazard Declaration: H302; H315; H319; H335

Gefitinib (ZD1839) (INN, , trade name Iressa, marketed by AstraZeneca and Teva), is a drug used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR. However, meta-analyses have not shown any improvement in overall survival, that is, it does not extend life.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.